A potent MAPK13-14 inhibitor prevents airway inflammation and mucus production
Shamus P. Keeler, Kangyun Wu, Yong Zhang, Dailing Mao, Ming Li, Courtney A. Iberg, Stephen R. Austin, Samuel A. Glaser, Jennifer Yantis, Stephanie Podgorny, Steven L. Brody, Joshua R. Chartock, Zhenfu Han, Derek E. Byers, Arthur G. Romero, Michael J. Holtzman
Abstract
This study describes the discovery of a potent mitogen-activated protein kinase 13-14 (MAPK13-14) inhibitor and its effectiveness in models of respiratory airway disease. The findings thereby provide a scheme for pathogenesis and therapy of lung diseases [e.g., asthma, chronic obstructive pulmonary disease (COPD), Covid-19, postviral, and allergic respiratory disease] and related conditions that implicate MAPK13-14 function. The findings also refine a hypothesis for epithelial and immune cell functions in respiratory disease that features MAPK13 as a possible component of this disease process.